[177Lu]Lu-PSMA-617 is currently evaluated in a Phase III study (https://clinicaltrials.gov/ct2/show/NCT03511664?term=PSMA&cond=Prostate+Cancer&phase=2&draw=5&rank=2 2020) and moreover, PSMA-targeted α-therapy was introduced as a further salvage therapy of end-stage mCRPC (Chakravarty et al. 2018). Here, FOLH1 is linked to urogenital neoplasm.